EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Nisotirostide (LY3457263), a novel NPY2 receptor agonist for type 2 diabetes and obesity: From discovery to clinical proof of concept

Daniel A Briere, Jennifer K Leohr, Helle Linnebjerg, Avinash Muppidi, Meghan Antonellis, Patrick Antonellis, Todd M Suter, Elizabeth Smith LaBell, Daniel Lopes, Mridula Dogra, Tamer Coskun, Jorge Alsina-Fernandez und 1 weitere

Molecular Metabolism · 2026-12 · 114 · 102452

DOI: 10.1016/j.molmet.2026.102452 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Molecular Metabolism, 2026-12. Verfasst von Daniel A Briere und 12 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, IN, USA. Electronic address: briere_daniel_a@lilly.com. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Receptors, Neuropeptide Y, Obesity, Hypoglycemic Agents. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/OBJECTIVES: Nisotirostide is a novel selective NPY2 receptor agonist under development as adjunctive therapy for people with type 2 diabetes (T2D) on glucagon-like peptide-1 receptor agonists (GLP-1 RA). METHODS: Nisotirostide binding affinity and potency were determined against human NPY2 receptor. Effects of nisotirostide on body weight, food intake, body composition, glucose, and insulin were evaluated in mouse models. A Phase 1 study in healthy participants and participants with T2D on 1.5 mg once-weekly dose of dulaglutide evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics, following a single subcutaneous dose of nisotirostide ranging from 0.025 to 1 mg. RESULTS: Nisotirostide potently and selectively activated NPY2 receptor signaling in vitro. In mice, nisotirostide reduced body weight by up to 12% as monotherapy and up to 31% when combined with GLP-1 RA, demonstrating synergism. Nisotirostide-treated mice showed improved glucose control, independent of weight loss. In Phase 1 clinical study (N = 65), PK of nisotirostide supported a once-weekly dosing regimen. A 1 mg dose of nisotirostide in monotherapy reduced mean body weight by 0.75 kg versus placebo (ns); when added to dulaglutide, up to 2.58 kg reduction was observed versus dulaglutide alone (p < 0.05). Gastrointestinal adverse events, such as nausea and vomiting, were the most commonly reported with nisotirostide; these were dose-dependent and mild-to-moderate in severity. CONCLUSIONS: Nisotirostide demonstrated potent, selective NPY2R agonism with a PK profile supporting once-weekly dosing. Preclinical metabolic benefits, including weight-independent glucose improvements, translated clinically, and a manageable tolerability profile supports further development as adjunctive GLP-1 RA therapy for T2D and obesity. CLINICALTRIALS: gov number: NCT04641312.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Receptors, Neuropeptide YObesityHypoglycemic AgentsHumansAnimalsMiceMaleFemaleAdultRecombinant Fusion ProteinsMiddle AgedGlucagon-Like PeptidesImmunoglobulin Fc FragmentsBlood GlucoseGlucagon-Like Peptide-1 Receptor AgonistsMice, Inbred C57BL

Stichwörter der Autor:innen

Glycemic controlNPY receptorPYYType 2 diabetesWeight management

Substanzen

Receptors, Neuropeptide YHypoglycemic Agentsdulaglutideneuropeptide Y2 receptorRecombinant Fusion ProteinsGlucagon-Like PeptidesImmunoglobulin Fc FragmentsBlood GlucoseGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Eli Lilly and Company, IN, USA. Electronic address: briere_daniel_a@lilly.com.
  • Eli Lilly and Company, IN, USA.

Förderung

  • Eli Lilly and Company

Zitieren

APA

Briere, D. A., Leohr, J. K., Linnebjerg, H., Muppidi, A., Antonellis, M., Antonellis, P., Suter, T. M., Smith LaBell, E., Lopes, D., Dogra, M., Coskun, T., Alsina-Fernandez, J., & Mather, K. J. (2026). Nisotirostide (LY3457263), a novel NPY2 receptor agonist for type 2 diabetes and obesity: From discovery to clinical proof of concept. Molecular Metabolism, 114, 102452. https://doi.org/10.1016/j.molmet.2026.102452

Vancouver

Briere DA, Leohr JK, Linnebjerg H, Muppidi A, Antonellis M, Antonellis P, et al. Nisotirostide (LY3457263), a novel NPY2 receptor agonist for type 2 diabetes and obesity: From discovery to clinical proof of concept. Molecular Metabolism. 2026;114:102452. doi:10.1016/j.molmet.2026.102452

BibTeX
@article{Briere2026,
  author = {Briere, Daniel A and Leohr, Jennifer K and Linnebjerg, Helle and Muppidi, Avinash and Antonellis, Meghan and Antonellis, Patrick and Suter, Todd M and Smith LaBell, Elizabeth and Lopes, Daniel and Dogra, Mridula and Coskun, Tamer and Alsina-Fernandez, Jorge and Mather, Kieren J},
  title = {Nisotirostide (LY3457263), a novel NPY2 receptor agonist for type 2 diabetes and obesity: From discovery to clinical proof of concept},
  journal = {Molecular Metabolism},
  year = {2026},
  volume = {114},
  pages = {102452},
  doi = {10.1016/j.molmet.2026.102452}
}
Kostenlos starten →